CA2825894C — Prognosis of cancer using a circulating biomarker
Assigned to Amgen Inc · Expires 2021-11-30 · 4y expired
What this patent protects
' 81772359 ABSTRACT The present disclosure features the use of ganitumab for treating a patient having a cancerous condition. By measuring the amount of a circulating biomarker in a sample from the patient, the patient is assessed to have a better prognosis of a ganitumab-depende…
USPTO Abstract
' 81772359 ABSTRACT The present disclosure features the use of ganitumab for treating a patient having a cancerous condition. By measuring the amount of a circulating biomarker in a sample from the patient, the patient is assessed to have a better prognosis of a ganitumab-dependent increase in overall survival. Such biomarkers include total IGF-2 or free 1GF-2.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.